| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |